Skip to main content

Table 2 Prescribed treatment, supportive drugs and related outcome (n = 82)

From: Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients

Cate n (%)
Prescribed DAAs
 SOF + RBV 10 (12.2)
 SOF + SIM ± RBV 29 (35.4)
 SOF + LDV ± RBV 31 (37.8)
 SOF + DCV ± RBV 12 (14.6)
Ribavirin
 Yes 49 (59.7)
 No 33 (40.3)
Ribavirin modification
 None 26 (53.1)
 Reduction 22 (44.9)
 Suspension 1 (2)
Adding support drug for anaemia in patients with ribavirin
 None 38 (77.6)
 Folic acid 7 (14.2)
 Erythropoietin 2 (4.1)
 Folic acid + erythropoietin 2 (4.1)
Reason for stopping DAAs
 End of treatment 80 (97.6)
 Patient decision 1 (1.2)
 Virological failure 1 (1.2)
  1. DAAs Direct antiviral agents, SOF Sofosbuvir, RBV Ribavirin, SIM Simeprevir, LDV Ledipasvir, DCV Daclatasvir